The kinase inhibitor field is maturing.

CHI and Bio-IT World Present the Thirteenth Annual Structure-Based Drug Design: Genome to Drug Lead with Big Data Approach conference, June 19-21, 2013, Boston, MA, will cover developments in in silico technology, as well as experimental approaches useful

Cambridge Healthtech Institute is proud to announce The Clinical Epigenome Conference (TCEC), June 26-27 in San Francisco, highlighting the interplay between disease-genome-epigenome, while exploring the profound opportunities of applying epigenomic analy

The advancing technology of high-throughput screening is changing the type of molecules found. With protein function more physiologically relevant, the quality of the molecules that pharmacologists and medicinal chemists must deal with is changing. This course will familiarize researchers with the tools needed to exploit this potentially fruitful area of new drug discovery through discussion of allosteric molecules, detection of allosterism, and quantifying allosterism for chemical lead optimization.

Cancer stem cells (CSCs) have been identified in several types of cancer, and may play a role in tumorigenic growth, metastasis, and therapeutic resistance. New anticancer therapeutics are being developed that will inhibit tumor growth and reduce tumor-initiating cell frequency, improving clinical cancer therapy. The development of new agents that block key CSC pathways will be described, as well as a novel assay for tracking CSCs in cell populations without the need to isolate them, and a CSC screening strategy for discovering therapeutic antibodies.

The effective information flow and translation of accumulated knowledge across various antibody development stages remains a major challenge. Successful strategies for development of monoclonal antibodies require integration of relevant knowledge with respect to target antigen properties, antibody design criteria such as affinity, isotype selection, pharmacokinetic (PK)-pharmacodynamic (PD) properties, and antibody cross-reactivity across species from the early stages of antibody development. Biophysical measurements are one of the critical components necessary for the design of effective translational strategies for lead selection and evaluation of the relevant animal species for preclinical safety and efficacy studies. Incorporation of effective translational strategies from the early stages of the antibody development process is a necessity; when considered it not only reduces development time and cost, but also fosters implementation of rational decision making throughout all phases of antibody development.